Literature DB >> 2848122

Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors.

B Ashby1.   

Abstract

The shape of the time-course of cyclic AMP formation by intact human platelets in response to the stable prostaglandin I2 analogue iloprost varied with the concentration of the prostaglandin. At low concentrations of iloprost, the time-course showed a rise to a plateau with little subsequent decrease in cyclic AMP level. At high concentrations of iloprost, the initial rate of cyclic AMP formation was more rapid than at low concentrations, but the curves showed a marked time-dependent fall in cyclic AMP level to values below those observed at lower prostaglandin concentration. By contrast, PGE1 gave a rise and marked fall in cyclic AMP level at all concentrations of the prostaglandin and the curves did not cross. The time- and concentration-dependent fall in cyclic AMP level in response to iloprost was still apparent in the presence of phosphodiesterase inhibitors, indicating that inhibition of adenylate cyclase, rather than activation of cyclic AMP phosphodiesterases, was responsible for the fall in cyclic AMP level. Activators of protein kinase C, which phosphorylates platelet Ni and impairs its function, abolished the time-dependent fall in cyclic AMP level, indicating that Ni may be involved in prostaglandin-induced inhibition of adenylate cyclase. Time-courses were analyzed using an equation derived by Barber et al. (Adv. Cyc. Nuc. Res. 9, 507-516 (1978)) to yield rate constants for activation and inhibition of adenylate cyclase. Because of the difference in prostaglandin dependence of the activation and inhibition rate constants we propose that activation of adenylate cyclase in platelets is mediated by a rapid-acting stimulatory receptor, while time-dependent inhibition (desensitization) is mediated through a separate, slow-acting inhibitory receptor. The stimulatory receptor has an affinity for prostaglandin greater than the putative inhibitory receptor in the case of iloprost (as well as PGI2 and PGD2), and a lower affinity than the inhibitory receptor in the case of PGE1 (and PGE2). Prostaglandin-induced inhibition may be mediated through Ni.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848122

Source DB:  PubMed          Journal:  Second Messengers Phosphoproteins        ISSN: 0895-7479


  12 in total

1.  Prostaglandin-concentration-dependent desensitization of adenylate cyclase in human erythroleukaemia (HEL) cells is abolished by pertussis toxin and enhanced by induction by dimethyl sulphoxide.

Authors:  B Ashby; G O Almonor; E Wernick; M A Selak
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

2.  The effect of inhibitors of platelet aggregation on the metabolism of platelet-activating factor (PAF) in washed rabbit platelets.

Authors:  C O'Neill; A J Ammit; R Korth; S Fleming; X Wells
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Ligands to the platelet fibrinogen receptor glycoprotein IIb-IIIa do not affect agonist-induced second messengers Ca2+ or cyclic AMP.

Authors:  J A Williams; B Ashby; J L Daniel
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

4.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.

Authors:  J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

5.  cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity.

Authors:  P G Grant; A F Mannarino; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 6.  Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Authors:  Eitan A Friedman; Martin L Ogletree; Elias V Haddad; Olivier Boutaud
Journal:  Thromb Res       Date:  2015-05-28       Impact factor: 3.944

7.  Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients.

Authors:  R Stratton; X Shiwen; G Martini; A Holmes; A Leask; T Haberberger; G R Martin; C M Black; D Abraham
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 8.  Who is the real 12-HETrE?

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Prostaglandins Other Lipid Mediat       Date:  2017-03-01       Impact factor: 3.072

9.  Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels.

Authors:  E J Hide; C Thiemermann
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.

Authors:  J S Matthews; R L Jones
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.